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We investigated Clostridium difficile in calves and the
similarity between bovine and human C. difficile PCR ribo-
types by conducting a case-control study of calves from 102
dairy farms in Canada. Fecal samples from 144 calves with
diarrhea and 134 control calves were cultured for C. difficile
and tested with an ELISA for C. difficile toxins A and B.
C. difficile was isolated from 31 of 278 calves: 11 (7.6%) of
144 with diarrhea and 20 (14.9%) of 134 controls (p =
0.009). Toxins were detected in calf feces from 58 (56.8%)
of 102 farms, 57 (39.6%) of 144 calves with diarrhea, and
28 (20.9%) of 134 controls (p = 0.0002). PCR ribotyping of
31 isolates showed 8 distinct patterns; 7 have been identi-
fied in humans, 2 of which have been associated with out-
breaks of severe disease (PCR types 017 and 027). C.
difficile may be associated with calf diarrhea, and cattle
may be reservoirs of C. difficile for humans.
C
lostridium difficile, a gram-positive, spore-forming,
anaerobic bacterium, has been associated with
pseudomembranous colitis and nosocomial and antimicro-
bial drug–associated diarrhea in humans (1). Recently,
research has suggested that the frequency, severity, and
relapse of C. difficile–associated disease (CDAD) are
increasing in Europe and North America (1,2). The most
common risk factor for CDAD in humans is the use of
antimicrobial drugs, particularly fluoroquinolones (3–5).
Of recent concern, hypervirulent C. difficile strains have
been associated with outbreaks of severe CDAD (2,6).
The pathophysiology of CDAD involves colonization
of the intestinal tract with C. difficile and production of its
toxins (7–9). At least 3 cytotoxins are currently described
for C. difficile: toxins A and B (glucosyltransfersases) and
a binary toxin (CDT, ADP-ribosyltransferase) (10). Toxins
TcdA and TcdB are encoded by 2 separate genes, tcdA and
tcdB, located in a 19.6-kb pathogenicity locus (PaLoc).
The expression of these 2 genes is regulated by a putative
negative regulator within PaLoc, the tcdC gene (11).
Deletions in tcdC are believed to result in overexpression
of tcdA and tcdB and increased production of toxins A and
B, which may account for the apparent higher pathogenic-
ity in certain ribotypes (i.e., PCR type 027) (1). Some
strains also produce binary toxin, which is encoded by the
genes cdtA and cdtB located outside PaLoc (10). The role
of binary toxin in disease is currently under investigation
(12). Isolates producing >1 of these toxins (A, B, or bina-
ry) are currently referred to as toxigenic strains (10). C.
difficile also appears to be an important cause of enteric
disease in other species, including horses, dogs, and pigs
(7,8,13,14).
Neonatal calf diarrhea (NCD) is a common cause of ill-
ness (10.2%) and death in preweaning calves (15). A vari-
ety of enteropathogens have been implicated in NCD;
however, many cases are currently idiopathic (16).
Although  C.  difficile infection has been suggested as a
cause of diarrhea and enteritis in calves (17), further pub-
lished evidence is lacking. The objectives of this study
were to evaluate the role of C. difficile in NCD, genotypi-
cally and phenotypically characterize isolates from calves,
and compare calf and human isolates.
Materials and Methods
Farms and Calves
Atotal of 102 dairy farms in southern Ontario, Canada,
were included in the study. Farms were visited from May
through September 2004 to obtain 1 fecal sample from
calves <1 month of age. Fecal samples (>4 g) were
obtained from 10 consecutively born calves per farm.
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scoring system and then stored at 4°C within 6 hours of
collection. A score of 1 represented hard, dry fecal matter;
score 2, pasty and sticky feces; score 3 soft feces; and
score 4, watery feces that would adopt the shape of the
container immediately after sampling. Samples with a
score of 4 were considered to have diarrhea, whereas
scores of 1 and 2 were controls. Samples with a score of 3
were discarded to reduce selection bias. Selected samples
were recoded for blinding purposes and stored at –70°C
within 24 hours of collection. Aquestionnaire that request-
ed information about colostrum quality and administration,
diet, housing, cleaning and disinfection practices, antimi-
crobial or antiprotozoal feed supplements, level of nose-to-
nose contact among calves, vaccination of dams, and
dehorning was administered on each farm to investigate
risk factors for C. difficile in feces.
C. difficile Culture and Detection of Toxins A and B
Fecal samples were processed within 2 hours after
thawing. Enrichment culture was performed as previously
described (7,18). Briefly, ≈1 g of homogenized fecal mat-
ter was mixed with 2 mL of 96% ethanol and agitated at
room temperature for 50 minutes to select for bacterial
spores. The sediment was recovered after centrifugation at
3,800 × g for 10 minutes and resuspended in 5 mL of
cycloserine-cefoxitin fructose broth (C. difficile agar and C
difficile supplement SR0096; Oxoid, Columbia, MD,
USA) that was incubated anaerobically at 37°C for 7 days.
This broth was treated with 96% ethanol (1:1 vol/vol), cen-
trifuged at 3,800 × g for 10 minutes, and the sediment was
resuspended in 200 µL of sterile deionized water.
Thereafter, 200 µL of sediment was streaked onto
cycloserine-cefoxitin fructose agar and blood agar that
were incubated anaerobically at 37°C. Plates were evaluat-
ed in an anaerobic environment daily for <5 days. If
present, at least 2 colonies (swarming, flat, rough, non-
hemolytic) were subcultured. C. difficile was identified by
Gram stain (spore-forming gram-positive rods) and detec-
tion of L-proline aminopeptidase activity (Pro Disc,
Remel, Lenexa, KS, USA) (19). Isolates were stored at
–70°C until molecular analyses were performed.
Feces were screened for C. difficile toxins A and B by
using an ELISA (Tox A/B ELISA, TechLab, Blacksburg,
VA, USA) (20). The test was performed per manufactur-
er’s instructions. Two observers interpreted the reactions in
a blinded fashion.
Extraction of DNA
DNA was extracted by using a Chelex resin-based kit
(InstaGene Matrix, Bio-Rad, Laboratories, Hercules, CA,
USA) (21). After centrifugation of the C.  difficile
DNA–containing solutions, 125 µL of supernatant was
collected and stored at –20°C as a template for PCR
analyses.
PCR Ribotyping
PCR ribotyping analyses were performed as previously
described (22). DNA was amplified by using a thermal
cycler (Touchgene Gradient, Techne Inc., Burlington, NJ,
USA). Ribotype patterns were compared visually with C.
difficile PCR ribotypes from humans and other animals
from the provinces of Ontario, Quebec, and Manitoba,
Canada. The first isolate identified for each PCR ribotype
was submitted to the Anaerobe Reference Laboratory,
University Hospital of Wales, Cardiff, United Kingdom,
for comparison (23).
Detection of tcdA, tcdB, tcdC, and cdtB Genes
Amplification of nonrepeating and repeating sequences
of the tcdA gene and the nonrepeating sequences of the
tcdB gene was performed as previously described (24).
Identification of tcdC and cdtB genes was based on previ-
ous protocols (11,24,25). Reference strains were included
as positive and negative controls in every experiment.  
Antimicrobial Drug Susceptibility Tests
MICs for metronidazole, clindamycin, levofloxacin,
and vancomycin were determined by using the E-test
method (AB Biodisk, Solna, Sweden) (26). A McFarland
standard 1 suspension of pure C.  difficile colonies was
placed on Muller-Hinton blood agar plates (Oxoid,
Basingstoke, UK). After 48 hours of anaerobic incubation,
MICs were determined by consensus of 2 observers. 
Toxinotyping of C. difficile Strains
Toxinotyping analysis involved amplification and
enzymatic restriction of PCR fragment A3 of tcdA and
PCR fragment B1 of tcdB. This was performed following
a previously published protocol (27).
Other Enteropathogens
Because intestinal cryptosporidiosis was common
(40.6%) in dairy calves <28 days of age in the study area
(16), samples examined for C. difficile were also tested for
Cryptosporidium spp. oocysts (sucrose wet mount test) to
control for potential interactions regarding diarrhea. Other
calf enteropathogens were not investigated because they
are less prevalent in the region (L.A. Trotz-Williams et al.,
unpub. data).
Statistical Analysis
Multivariate stepwise logistic regression analyses were
performed by using SAS statistical software (SAS
Institute, Cary, NC, USA). Associations between farm
management data, age, sampling month, and results from
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model procedure (GenMod in SAS). Variables associated
with diarrhea and C. difficile or its toxins in feces were
investigated. During initial model building, variables with
p<0.15 were selected to construct final models. Parameters
were considered statistically significant if p values were
<0.05. A generalized linear mixed model controlling for
farm as a random effect was used to estimate and test the
farm variance component. Relationships between C. diffi-
cile toxins and diarrhea and between C. difficile toxins and
the age and month of sampling were investigated in the
models. Pairwise comparisons of least square means were
performed, and approximated Tukey adjusted p values
were computed. Reported exact p values, odd ratios (ORs),
and 95% confidence intervals (CIs) were determined with
exact conditional logistic regression tests by using
LogXact 5 software (Cytel Inc., Cambridge, MA, USA)
when analyses did not yield exact values with SAS
software.
Results
A total of 278 calves were studied: 144 with diarrhea
and 134 controls. The mean age of the sample was 14.2
days (range 5–30 days); 39 calves were 5–7 days of age,
107 were 8–14 days of age, 96 were 15–21 days of age,
and 32 were 22–30 days of age. Four calves had no age
recorded and were not used for descriptive information
regarding age. The mean ages of the control calves (14.8
days, 95% CI 13.7–15.9) and calves with diarrhea (13.9
days, 95% CI 13.0–14.7) were not significantly different
(p = 0.16).
C. difficile was isolated from 31 (11.2%) of 278 calves
from 25 (25%) of 102 farms. This bacterium was more
commonly identified in feces from control calves (14.9%,
20/134) than in feces from calves with diarrhea (7.6%,
11/144) (OR 3.47, 95% CI 1.27–10.24, exact 2-tailed p =
0.009).
C. difficile toxins Aand B were identified in feces of 85
(30.6%) of 278 calves from 58 (56.8%) of 102 farms: 57
(39.6%) of 144 calves with diarrhea and 28 (20.9%) of 134
controls (OR 3.07, 95% CI 1.62–5.96, exact 2-tailed p =
0.0002). C. difficile and its toxins were detected concur-
rently in only 6 (4.2%) of 144 calves with diarrhea and in
7 (5.2%) of 134 controls. 
Generalized linear mixed model analysis with farm as a
random effect showed no farm variance component (coef-
ficient 0). Thus, farm was included in subsequent models
as a fixed effect. Generalized linear model analyses
showed that none of the farm management practices sur-
veyed were associated with diarrhea or C. difficile test
results. Conversely, the month of sampling (p = 0.008) and
the age of the calves (p = 0.005) were significant variables
when modeling for the ELISA result as the outcome. May,
June, and July were associated with higher ORs of yield-
ing a positive fecal C. difficile toxin test result than was
August (Table 1). 
When the association with age was analyzed, a linear
relationship was found between age of calves and proba-
bility of a positive test result for C. difficile toxins. Fecal
samples from older calves were less likely than samples
from younger calves to be positive for C. difficile toxins;
the estimated OR was 2.0 for every 10 days of age differ-
ence at any point from 5 and 30 days of age (natural
antilogarithm of [0.0691 × no. of days of interest]; 95% CI
1.22–3.24, p = 0.006). No association was found between
administration of feed supplemented with oxytetracycline
(33 calves on 11 farms) or anticoccidial drugs (251 calves
on 91 farms) and C. difficile and its toxins in feces.
Cryptosporidium spp. oocysts in feces were significant-
ly associated with diarrhea and identified in 80 (55.9%) of
144 calves with diarrhea and 19 (14.2%) of 134 control
calves (OR 8.23, 95% CI 4.35–16.26, exact 2-tailed
p<0.0001). However, generalized linear model analysis
showed no interaction between Cryptosporidium spp. and
C. difficile toxins (p>0.5) or between Cryptosporidium
spp. and C. difficile culture (p>0.58).
Eight calf PCR ribotypes were identified among 31 C.
difficile isolates (Figure). Of these, 7 ribotypes represented
by 30 (96.7%) isolates were toxigenic (Table 2). Isolates
from 5 ribotypes had the classic tcdC fragment, and ribo-
types A11 and F12 had the major type A deletion (≈39 bp
deletion) (Table 2). Isolates of ribotype D189 had a tcdC
fragment, which is indicative of either a type B or C dele-
tion (≈18 bp).
The MIC range, MIC50, MIC90, and the percentage of
resistant C. difficile isolates are shown in Table 3. All 30
isolates tested were susceptible to metronidazole and van-
comycin. The prevalence of resistance for clindamycin and
levofloxacin was similar (73%, 22/30 isolates), but 18
(82%) of the 22 resistant isolates were resistant to both
antimicrobial drugs. Calf ribotypes A11 (5/9 isolates), B89
(9/9), C129 (2/2), and D189 (4/4) were overrepresented
among the resistant isolates.
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collection of 25 ribotypes of C. difficile isolated from
humans showed that 3 calf ribotypes representing 17
(54.8%) of 31 isolates were indistinguishable (calf ribo-
types B89 and D189) or similar (calf ribotype C129) to
ribotypes associated with CDAD in humans in Ontario and
Quebec (Figure). Ribotype B89, a strain that produces
toxin B but not toxin A, was indistinguishable from a strain
obtained from patients during a nosocomial outbreak of
CDAD in Manitoba, Canada (Figure) (28). When com-
pared with a collection of canine isolates from southern
Ontario (29), this ribotype was also identified in healthy
dogs (Figure). Isolates B89 and D89 were not clustered;
they were isolated from farms distributed across the stud-
ied region with ≈500 km between the most distant ones.
Comparison of 7/8 calf ribotypes (representing 30/31 iso-
lates) with a C.  difficile PCR ribotype library at the
Anaerobe Reference Laboratory, University Hospital of
Wales, Cardiff, United Kingdom, that contained >160 C.
difficile ribotypes showed that all bovine ribotypes have
been identified in humans (Table 2). Toxinotyping of iso-
lates from calf ribotypes B89/ARL-UK PCR ribotype 017
and D189/ARL-UK PCR type 027 indicated that they were
toxinotypes VIII and III, respectively. Other calf ribotypes
were not toxinotyped.
Discussion
This study has demonstrated that shedding of C. diffi-
cile is common in dairy calves in Ontario regardless
whether they have enteric disease. The overall prevalence
of shedding (11.2%) was similar to that previously report-
ed (17). However, that shedding of C. difficile was more
common in control animals was surprising, particularly
because 96.7% of the isolates were toxigenic. The reason
for this finding is unclear, and natural and methodologic
reasons should be considered. Whether the isolation
method used in this study resulted in identification bias in
favor of 1 of the groups (i.e., control animals) is not
known. Pretreatment of fecal samples with ethanol has
been shown to facilitate the recovery of C. difficile in
asymptomatic humans (18). However, how this method
would work in calves with and without diarrhea is
unknown. The dilutional effect of watery stools could have
prevented C. difficile from being isolated from calves with
diarrhea, or C. difficile may not be a primary pathogen in
calves. In addition, the concentration of C. difficile in the
Clostridium difficile PCR Ribotypes in Calves
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 11, November 2006 1733
Figure. Clostridium difficile PCR ribotypes of bovine origin (dairy
calves), Ontario, Canada, 2004. *Calf isolate classified as PCR
ribotype 017 at the Anaerobe Reference Laboratory, University
Hospital of Wales, Cardiff, United Kingdom. Isolates of human
(lane 1), calf (lane 2), and canine (lane 3) origin identified in
Ontario are indistinguishable. The first and tenth wells contain
100-bp molecular mass markers.intestinal tract may not correlate with the concentration of
spores in feces. Since quantitative culture was not per-
formed in this study, conclusions cannot be made.
The pathophysiology and epidemiology of C. difficile
are not completely understood in humans, and some stud-
ies have reported that asymptomatic colonization with C.
difficile may have a protective effect against CDAD (30).
In humans, 50%–80% of asymptomatic infants may be
colonized with toxigenic C. difficile and have its toxins in
their feces (31).  C.  difficile has been reported to affect
neonatal foals and piglets (7,8).
Detection of toxins A and B in feces of humans with
diarrhea is considered diagnostic for CDAD (31,32). The
positive association between fecal C. difficile toxins and
calf diarrhea found in our study indicates that C. difficile
might be a pathogen in calves. However, the clinical rele-
vance of this association is uncertain because it is based on
the assumption that the ELISA used has acceptable sensi-
tivity and specificity in calves. The validity of this ELISA
has not been reported for most animal species, including
cattle. For humans and piglets, adequate sensitivities and
specificities for this ELISA (65%–95% and 95%–100%,
respectively) (20,32,33) contrast with recently reported
suboptimal performance for canine feces (34). With an
apparent interspecies variability of the ELISA, validation
of this test for bovine feces is required before conclusions
regarding causal associations can be made.
The finding that calves were more likely to have
detectable levels of C. difficile toxins in their feces early in
life is consistent with findings of a previous study (17).
The reason for this is unclear, although C. difficile may be
better able to colonize, proliferate, and produce toxins in
younger animals with less developed intestinal microflora.
In other animal species and humans, administration of
antimicrobial drugs is considered a predisposing factor for
development of CDAD (3,7,35,36). No statistical associa-
tions were identified in this regard at the calf level because
questionnaires were designed to explore farm practices.
Molecular analyses showed that a relevant proportion
of the C. difficile isolates (9/31) had tcdB genes but not
tcdA genes (A–B+). These variant isolates are uncommon
in humans but have been reported in association with out-
breaks of CDAD (2,36). In a previous study in calves, no
A–B+ isolates were identified (17). This discrepancy
could be due to potential differences between the 2 study
populations. 
In our study, the 9 calf A–B+ isolates and a control
strain were classified as ribotype pattern B89 type 017
(Figure). This ribotype has been reported in outbreaks of
CDAD in humans in various countries (2,28,36), including
the Canadian provinces of Ontario, Quebec, and Manitoba,
from which the human control strain was obtained (28).
Toxinotyping (type VIII) and tcdC analysis (classic gene)
of these 9 calf isolates supported their similarity to human
strains. The epidemiologic explanation for the presence of
this human epidemic strain in calves and in healthy dogs
(29) is uncertain, but this finding raises the concern of
potential animal-to-human transmission and vice versa. No
isolates of bovine origin were available for additional ret-
rospective comparisons.
The second major calf ribotype common to humans in
Ontario and Quebec was D189/PCR ribotype 027 (positive
for tcdA, tcdB and cdtB, type B tcdC deletion, and toxino-
type III). Molecular characteristics of this ribotype indicate
that it is a hypertoxin-producing ribotype recently reported
as a cause of serious outbreaks of disease in humans in
North America and Europe (1). In Quebec, Canada, C. dif-
ficile type 027 was isolated during an outbreak from 67%
of persons with hospital-acquired CDAD and 37% of per-
sons with community-acquired CDAD (1). The pathogenic-
ity of this ribotype is believed to be associated with a high
production of toxins A and B in vitro, and with fluoro-
quinolone resistance (3,4). 
The 4 calf isolates of PCR D189/ribotype 027 identified
in our study were not geographically clustered. This result
and the recent finding of this strain in a dog in Ontario indi-
cate that this C. difficile ribotype may be widely dissemi-
nated in the community in different animal species (37).
The public health consequences of this are unclear and
require further study. Whether cattle could play a role in
dissemination of this strain through direct contact, environ-
mental contamination, or the food chain should be deter-
mined. Although C. difficile is not considered a foodborne
pathogen, it has been identified in raw meat intended for pet
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Ontario (A. Rodriguez-Palacios et al., unpub. data).
Results of antimicrobial drug susceptibility tests for
metronidazole, vancomycin, and clindamycin are consis-
tent with those of previous reports in humans, in which
antimicrobial susceptibility of C.  difficile strains to
metronidazole and vancomycin was ≈100% and antimicro-
bial resistance to clindamycin was ≈70%–80% (2,26,35).
Most isolates (73%) were resistant to levofloxacin, which
is not administered to cattle. Antimicrobial drug resistance
to fluoroquinolones has been described in C. difficile PCR
ribotype 027 as a major risk factor for development of
CDAD (4,5). The development of fluoroquinolone resist-
ance in human-derived strains has been hypothesized to
result from increased use of these antimicrobial drugs,
which has also been associated with a higher risk for
CDAD in hospitals (3,5).
Use of fluoroquinolones was not voluntarily reported
for any of the farms or calves in this study, and lev-
ofloxacin resistance cannot be extrapolated to other fluoro-
quinolones (39). In Canada, fluoroquinolones are not
approved for use in dairy cattle or veal calves.
Fluoroquinolones have not been approved for veterinary
use in any food-producing animals in Canada until recent-
ly, when a commercial enrofloxacin product was approved
only for use in beef cattle with unresponsive respiratory
disease (39). As part of a Canadian surveillance program,
Health Canada, through the Canadian Integrated Program
for Antimicrobial Resistance Surveillance, has monitored
fluoroquinolone resistance in strains of Escherichia coli
and  Salmonella spp. from beef cattle since 2001–2002.
According to the Canadian Integrated Program for
Antimicrobial Resistance Surveillance 2002 and 2003
reports, no resistance to fluoroquinolones has been
observed (40). Thus, the source of fluoroquinolone resist-
ance in calf-derived C.  difficile isolates in our study is
uncertain and is not substantiated on the hypothesis of
excessive use of fluoroquinolones, i.e., enrofloxacin, in
cattle. Whether this resistance has any epidemiologic asso-
ciation with companion animals (i.e., dogs) or humans for
which fluoroquinolones have been approved for many
years remains unknown.
The results of our study indicate that C. difficile may
play a role in neonatal calf diarrhea, which is a serious con-
cern in the bovine industry. Calf C. difficile isolates that are
indistinguishable from human strains and have fluoro-
quinolone resistance and tcdC deletions also raise the pos-
sibility of interspecies transmission. Although this study
did not confirm that infection with C. difficile is zoonotical-
ly transmitted, further study is indicated to evaluate this
possibility. Investigations of recent changes in the epidemi-
ology of CDAD and identification of new pathogenic geno-
types should also involve concurrent evaluation of animal
reservoirs or origins. Validation studies are also required to 
assess culture protocols and immunoassay tests for identifi-
cation of C. difficile and its toxins in cattle feces.
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